Author: Business Wire

愛爾康以獨立上市公司型態亮相

日內瓦–(BUSINESS WIRE)–(美國商業資訊)–致力於幫助人們擁有明亮雙眸的全球眼科保健領導者愛爾康(Alcon)今天宣佈以獨立上市公司型態亮相,並完成從諾華(Novartis)的拆分。該公司股票於今日起在瑞士證券交易所(SIX Swiss Exchange)和紐約證券交易所(NYSE)上市交易,交易代碼為“ALC”。 愛爾康是全球最大的眼科保健器材公司,其手術產品和視力保健產品業務相輔相成。該公司業務遍及全球74個國家,為140多個國家的病患服務,在新興市場的業務快速成長。愛爾康擁…

爱尔康作为独立上市公司亮相

日内瓦–(BUSINESS WIRE)–(美国商业资讯)–致力于帮助人们拥有明亮双眸的全球眼科保健领导者爱尔康(Alcon)今天宣布作为一家独立上市公司亮相,并完成从诺华(Novartis)的拆分。该公司股票于今日起在瑞士证券交易所(SIX Swiss Exchange)和纽约证券交易所(NYSE)上市交易,交易代码为“ALC”。 爱尔康是全球最大的眼科保健器械公司,其手术产品和视力保健产品业务相辅相成。该公司业务覆盖全球74个国家,为140多个国家的患者服务,在新兴市场的业务快速发展。爱尔康…

$12 Billion Contact Lenses Market – Global Outlook and Forecast 2019-2024 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Contact Lenses Market – Global Outlook and Forecast 2019-2024” report has been added to ResearchAndMarkets.com’s offering. The global contact lenses market is estimated to reach revenues of more than $12 billion by 2024, growing at CAGR of around 6% during 2018-2024. The advent of low-cost manufacturing techniques and the invention of new silicone hydrogel-based polymers will boost the demand for daily use, the disposable lens in the market. The leading vendors are

Global Anterior Uveitis Clinical Trials Review, H2, 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anterior Uveitis Global Clinical Trials Review, H2, 2018″ clinical trials has been added to ResearchAndMarkets.com’s offering. Anterior Uveitis Global Clinical Trials Review, H2, 2018” provides an overview of Anterior Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Anterior Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report

Juvenile Macular Degeneration (Stargardt Disease) Pipeline Review, H1 2019 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of admi